Skip to main content
 Filing · LD-2 quarterly report Q2 report
Reporting period
2nd Quarter 2026
Apr 1 - June 30 · Posted Jul 17, 2026
Expenses
$320,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
District of Columbia

Official filing document

 Government bodies contacted 7

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 6

Issues related to global trade and tariffs Issues related to United States-Mexico-Canada Agreement (USMCA)

Issues related to appropriations and user fee funding for the Food and Drug Administration

Issues related to the reauthorization of the Small Business Innovation Research (SBIR) Program

Issues relating to the the Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL) (H.R. 3152) and Patent Eligibility Restoration Act (PERA) (S. 1546) patent legislation

Issues related to MDUFA implementation; FDA staffing Issues relating to the medical product supply chain Issues related to medical device sterilization and the use of ethylene oxide to sterilize medical devices Issues related to HR 3723 - the Medical Device Electronic Labeling Act Issues related to PFAS and EtO Chemical regulation Issues related to cyber security Issues related to consumer and health data privacy Issues related to regulation of artificial intelligence in healthcare Issues related to HR 5662/S 2907 - the Medical Device Recall Improvement Act Issues related to competitive bidding Issues related to the National Defense Authorization Act (NDAA)

Issues related to Medicare coverage reform Issues related to the coverage for FDA Breakthrough products and the H.R. 5343 and S.1717 Ensuring Patient Access to Critical Breakthrough Products Act TCET Issues related to the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway Issues related to the New Technology Add on Payment (NTAP) Issues related to coverage of telehealth services Issues related to physician fee schedule Issues related to CMS expansion of prior authorization requirements for medical procedures Issues related to reimbursement of artificial intelligence in healthcare

 Bills named in this filing 6
  • H.R. 3152
    Patent Eligibility Restoration Act of 2025
  • S. 1546
    Patent Eligibility Restoration Act of 2025
  • H.R. 3723
    Medical Device Electronic Labeling Act
  • H.R. 5662
    Medical Device Recall Improvement Act
  • H.R. 5343
    Ensuring Patient Access to Critical Breakthrough Products Act
  • S. 1717
    Ensuring Patient Access to Critical Breakthrough Products Act of 2025

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem